More Good News for Boston Scientific’s Coronary IVL Tech

Why It Matters

The trial demonstrates that IVL can safely and effectively treat heavily calcified coronary lesions, potentially accelerating FDA clearance and expanding treatment options for high‑risk PCI patients.

Key Takeaways

• FRACTURE trial showed 93.3% 30‑day MACE‑free rate.
• Procedural success reached 93.7%, surpassing 85.8% target.
• No deaths; only one revascularization at 30‑day follow‑up.
• Results bolster FDA submission for Seismiq 4CE coronary IVL catheter.
• IVL therapy expected to expand in complex coronary PCI.

Pulse Analysis

Intravascular lithotripsy (IVL) has emerged as a breakthrough for tackling heavily calcified coronary plaques that traditional balloon angioplasty and atherectomy struggle to modify. By delivering acoustic pressure waves, IVL fractures calcium, improving vessel compliance and facilitating optimal stent expansion. The technology’s adoption has accelerated in both peripheral and coronary arenas, driven by the growing prevalence of coronary artery disease and the need for safer lesion preparation in complex percutaneous coronary interventions (PCI). Analysts project the IVL market to exceed $1 billion globally within the next five years, underscoring its commercial momentum.

Boston Scientific’s FRACTURE trial provides the most recent clinical validation for its Seismiq 4CE catheter, a dedicated coronary IVL system. The single‑arm study enrolled patients with severely calcified, treatment‑naïve lesions, achieving a 93.3% freedom‑from‑major‑adverse‑cardiac‑events rate at 30 days—well above the pre‑specified 86.2% benchmark. Procedural success, defined by successful stent delivery and adequate lesion preparation, reached 93.7% versus an 85.8% goal. Importantly, the trial reported zero procedural deaths and only one target‑vessel revascularization, highlighting a favorable safety profile that could differentiate Seismiq 4CE from competing IVL platforms.

The positive outcomes are now feeding Boston Scientific’s regulatory strategy. While the Seismiq 4CE catheter remains unapproved, the data bolster the company’s forthcoming FDA submission, positioning it to capture market share in a segment where few dedicated coronary IVL devices exist. Success could also stimulate broader insurer coverage and encourage clinicians to adopt IVL earlier in the PCI workflow, potentially improving long‑term outcomes for high‑risk patients. Competitors such as Shockwave Medical are also advancing their pipelines, suggesting a near‑term intensification of innovation and pricing dynamics in the coronary IVL space.